...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Report Of Exempt Distribution.
Reply New Message
Prev Message Back To Forum Threaded View Next Message

Another Report Of Exempt Distribution.

Promissory Note out the USA

Dated: April 25, 2024.

Amt: $342,225.00 CAN

With 250K Warrants, Expire, April 25, 2029 @ $0.82

 

Koo

 

 

1 Recommendations
Reply New Message
Prev Message Back To Forum Threaded View Next Message
Share
Share
New Message
Please login to post a reply